42017-89-0 | Fenofibric acid

Packsize	Purity	Availability	Price	Discounted Price
5g	98%	in stock	$6.00	$4.00
10g	98%	in stock	$7.00	$5.00
100g	98%	in stock	$43.00	$30.00
500g	98%	in stock	$213.00	$149.00

Description

• Catalog Number: AI50195
• Chemical Name: Fenofibric acid
• CAS Number: 42017-89-0
• Molecular Formula: C17H15ClO4
• Molecular Weight: 318.7516
• MDL Number: MFCD00792461
• SMILES: Clc1ccc(cc1)C(=O)c1ccc(cc1)OC(C(=O)O)(C)C
• NSC Number: 281318

Computed Properties

• Complexity: 405
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 22
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 5
• XLogP3: 3.9

Literature

• Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia.

  Journal of lipid research 20121101

• Synthesis of highly water-soluble fibrate derivatives via BGLation.

  Bioorganic & medicinal chemistry letters 20121015

• Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial.

  Cardiovascular drugs and therapy 20120801

• The toxicity potential of pharmaceuticals found in the Douro River estuary (Portugal): evaluation of impacts on fish liver, by histopathology, stereology, vitellogenin and CYP1A immunohistochemistry, after sub-acute exposures of the zebrafish model.

  Environmental toxicology and pharmacology 20120701

• Ethyl 2,4,6-trihydroxybenzoate is an agonistic ligand for liver X receptor that induces cholesterol efflux from macrophages without affecting lipid accumulation in HepG2 cells.

  Bioorganic & medicinal chemistry letters 20120615

• Beneficial effects of fenofibrate in retinal pigment epithelium by the modulation of stress and survival signaling under diabetic conditions.

  Journal of cellular physiology 20120601

• Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors.

  ChemMedChem 20120601

• A review of time courses and predictors of lipid changes with fenofibric acid-statin combination.

  Cardiovascular drugs and therapy 20120601

• Development of a sensitive liquid chromatography/tandem mass spectrometry method for the determination of fenofibric acid in rat plasma.

  Biomedical chromatography : BMC 20120401

• Novel phenoxyalkylcarboxylic acid derivatives as hypolipidaemic agents.

  Journal of enzyme inhibition and medicinal chemistry 20120401

• Biomolecular chemistry of isopropyl fibrates.

  Journal of pharmaceutical sciences 20120401

• A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease.

  Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 20120401

• One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20120401

• Fenofibric acid for hyperlipidemia.

  Expert opinion on pharmacotherapy 20120401

• LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.

  Journal of lipid research 20120301

• Relationship between paraoxonase and homocysteine: crossroads of oxidative diseases.

  Archives of medical science : AMS 20120227

• In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions.

  Pharmaceutical research 20120201

• A review of the rationale for additional therapeutic interventions to attain lower LDL-C when statin therapy is not enough.

  Current atherosclerosis reports 20120201

• Severe neutropenia in a renal transplant patient suggesting an interaction between mycophenolate and fenofibrate.

  Current drug safety 20120201

• Peroxisome proliferator-activated receptor activity is involved in the osteoblastic differentiation regulated by bone morphogenetic proteins and tumor necrosis factor-α.

  Molecular and cellular endocrinology 20120102

• Relaxation of rat thoracic aorta by fibrate drugs correlates with their potency to disturb intracellular calcium of VSMCs.

  Vascular pharmacology 20120101

• Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease.

  Clinical Medicine Insights. Cardiology 20120101

• Femtosecond transient absorption, nanosecond time-resolved resonance Raman, and density functional theory study of fenofibric acid in acetonitrile and isopropyl alcohol solvents.

  The journal of physical chemistry. A 20111215

• Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.

  Atherosclerosis 20111201

• Oxidation by-products and ecotoxicity assessment during the photodegradation of fenofibric acid in aqueous solution with UV and UV/H2O2.

  Journal of hazardous materials 20111030

• The toxicity potential of pharmaceuticals found in the Douro River estuary (Portugal): assessing impacts on gonadal maturation with a histopathological and stereological study of zebrafish ovary and testis after sub-acute exposures.

  Aquatic toxicology (Amsterdam, Netherlands) 20111001

• Ursolic acid is a PPAR-α agonist that regulates hepatic lipid metabolism.

  Bioorganic & medicinal chemistry letters 20111001

• The toxicity potential of pharmaceuticals found in the Douro River estuary (Portugal)--experimental assessment using a zebrafish embryo test.

  Environmental toxicology and pharmacology 20110901

• Synthesis and biological evaluation of orally active hypolipidemic agents.

  Journal of medicinal chemistry 20110825

• Fenofibric acid reduces fibronectin and collagen type IV overexpression in human retinal pigment epithelial cells grown in conditions mimicking the diabetic milieu: functional implications in retinal permeability.

  Investigative ophthalmology & visual science 20110801

• Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1β by suppressing AMP-activated protein kinase (AMPK) activation.

  Diabetologia 20110601

• Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials.

  Clinical therapeutics 20110601

• Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis.

  Current medical research and opinion 20110501

• Synthesis and pharmacological evaluation of novel benzoylazole-based PPAR α/γ activators.

  Bioorganic & medicinal chemistry letters 20110401

• Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.

  The American journal of cardiology 20110315

• Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin.

  Journal of clinical pharmacology 20110301

• Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus.

  Cardiovascular drugs and therapy 20110201

• Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides.

  Cardiovascular drugs and therapy 20110201

• Activation of peroxisome proliferator-activated receptor α in megakaryocytes reduces platelet-derived growth factor-BB in platelets.

  Journal of atherosclerosis and thrombosis 20110101

• Considering statins for cholesterol-reduction in children if lifestyle and diet changes do not improve their health: a review of the risks and benefits.

  Vascular health and risk management 20110101

• Food protein-stabilized nanoemulsions as potential delivery systems for poorly water-soluble drugs: preparation, in vitro characterization, and pharmacokinetics in rats.

  International journal of nanomedicine 20110101

• A systems biology strategy for predicting similarities and differences of drug effects: evidence for drug-specific modulation of inflammation in atherosclerosis.

  BMC systems biology 20110101

• Tissue factor, blood coagulation, and beyond: an overview.

  International journal of inflammation 20110101

• Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥ 2 mg/L). cmb@bcm.tmc.edu.

  Journal of clinical lipidology 20110101

• In situ formation of nanocrystals from a self-microemulsifying drug delivery system to enhance oral bioavailability of fenofibrate.

  International journal of nanomedicine 20110101

• Atorvastatin and fenofibric acid differentially affect the release of adipokines in the visceral and subcutaneous cultures of adipocytes that were obtained from patients with and without mixed dyslipidemia.

  Pharmacological reports : PR 20110101

• Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study.

  Cardiovascular drugs and therapy 20101201

• Effects of statins on the epicardial fat thickness in patients with coronary artery stenosis underwent percutaneous coronary intervention: comparison of atorvastatin with simvastatin/ezetimibe.

  Journal of cardiovascular ultrasound 20101201

• Catalytic ozonation of fenofibric acid over alumina-supported manganese oxide.

  Journal of hazardous materials 20101115

• Fenofibrate but not fenofibric acid inhibits 11beta-hydroxysteroid dehydrogenase 1 in C2C12 myotubes.

  Molecular and cellular biochemistry 20101101

• Human health risk assessment of pharmaceuticals in water: issues and challenges ahead.

  International journal of environmental research and public health 20101101

• Spatiotemporal distribution of pharmaceuticals in the Douro River estuary (Portugal).

  The Science of the total environment 20101015

• Unmetabolized fenofibrate, but not fenofibric acid, activates AMPK and inhibits the expression of phosphoenolpyruvate carboxykinase in hepatocytes.

  Life sciences 20101009

• Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia.

  American heart journal 20101001

• Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies.

  Clinical cardiology 20101001

• The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes.

  Drugs of today (Barcelona, Spain : 1998) 20101001

• The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.

  Diabetes care 20100901

• Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans.

  Journal of clinical pharmacology 20100801

• Caveolin-1 is enriched in the peroxisomal membrane of rat hepatocytes.

  Hepatology (Baltimore, Md.) 20100501

• Ligand-enhanced expression and in-cell assay of human peroxisome proliferator-activated receptor alpha ligand binding domain.

  Protein expression and purification 20100401

• Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid.

  Expert opinion on pharmacotherapy 20100401

• Ecotoxicity assessment of lipid regulators in water and biologically treated wastewater using three aquatic organisms.

  Environmental science and pollution research international 20100101

• Occurrence of emerging pollutants in urban wastewater and their removal through biological treatment followed by ozonation.

  Water research 20100101

• Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.

  Clinical drug investigation 20100101

• Medicinal chemistry of drugs used in diabetic cardiomyopathy.

  Current medicinal chemistry 20100101

• Effect of fenofibrate on uric acid metabolism and urate transporter 1.

  Internal medicine (Tokyo, Japan) 20100101

• Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20100101

• Cardiovascular computed tomographic assessment of the effect of combination lipoprotein therapy on coronary arterial plaque: rationale and design of the AFRICA (Atorvastatin plus Fenofibric acid in the Reduction of Intermediate Coronary Atherosclerosis) study.

  Journal of cardiovascular computed tomography 20100101

• Therapeutic options to further lower C-reactive protein for patients on statin treatment.

  Current atherosclerosis reports 20100101

• Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20100101

• Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia.

  Vascular health and risk management 20100101

• Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.

  Vascular health and risk management 20100101

• Role of PPARα and Its Agonist in Renal Diseases.

  PPAR research 20100101

• Pharmacokinetics and comparative bioavailability of two fenofibrate capsule formulations in healthy volunteers.

  Arzneimittel-Forschung 20100101

• Pitavastatin: evidence for its place in treatment of hypercholesterolemia.

  Core evidence 20100101

• A review on the rationale and clinical use of concomitant rosuvastatin and fenofibrate/fenofibric acid therapy.

  Clinical pharmacology : advances and applications 20100101

• Capecitabine-induced severe hypertriglyceridaemia and diabetes: a case report and review of the literature.

  Diabetic medicine : a journal of the British Diabetic Association 20091201

• In vitro glucuronidation of fenofibric acid by human UDP-glucuronosyltransferases and liver microsomes.

  Drug metabolism and disposition: the biological fate of chemicals 20091101

• Selective modulation of amyloid-beta peptide degradation by flurbiprofen, fenofibrate, and related compounds regulates Abeta levels.

  Journal of neurochemistry 20091101

• New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function.

  Journal of medicinal chemistry 20091022

• Probing the fibrate binding specificity of rat liver fatty acid binding protein.

  Journal of medicinal chemistry 20090910

• Determination of fenofibric acid in human plasma by ultra performance liquid chromatography-electrospray ionization mass spectrometry: application to a bioequivalence study.

  Biomedical chromatography : BMC 20090901

• Myopathy with statin-fibrate combination therapy: clinical considerations.

  Nature reviews. Endocrinology 20090901

• Peroxisome-proliferator-activated receptor-alpha activation protects brain capillary endothelial cells from oxygen-glucose deprivation-induced hyperpermeability in the blood-brain barrier.

  Current neurovascular research 20090801

• Advances in the medical treatment of diabetic retinopathy.

  Diabetes care 20090801

• IVIVC in oral absorption for fenofibrate immediate release tablets using a dissolution/permeation system.

  Journal of pharmaceutical sciences 20090601

• Characterization of lipophilic drug binding to rat intestinal fatty acid binding protein.

  Molecular and cellular biochemistry 20090601

• Fenofibrate metabolism in the cynomolgus monkey using ultraperformance liquid chromatography-quadrupole time-of-flight mass spectrometry-based metabolomics.

  Drug metabolism and disposition: the biological fate of chemicals 20090601

• Differentiated CaCo-2 cells as an in-vitro model to evaluate de-novo apolipoprotein A-I production in the small intestine.

  European journal of gastroenterology & hepatology 20090601

• Fenofibric Acid (trilipix).

  The Medical letter on drugs and therapeutics 20090504

• Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.

  Atherosclerosis 20090501

• Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.

  Bioorganic & medicinal chemistry letters 20090501

• Fenofibrate-loaded PLGA microparticles: effects on ischemic stroke.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20090411

• Statins and fenofibrate affect skeletal muscle chloride conductance in rats by differently impairing ClC-1 channel regulation and expression.

  British journal of pharmacology 20090401

• Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 3, 12-week randomized, controlled studies.

  Journal of clinical lipidology 20090401

• Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.

  The American journal of cardiology 20090215

• ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans.

  Journal of clinical pharmacology 20090101

• Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study.

  American heart journal 20090101

• MBX-102/JNJ39659100, a novel non-TZD selective partial PPAR-γ agonist lowers triglyceride independently of PPAR-α activation.

  PPAR research 20090101

• Regulation of sulfotransferase and UDP-glucuronosyltransferase gene expression by the PPARs.

  PPAR research 20090101

• Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk.

  Vascular health and risk management 20090101

• Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20090101

• Effect of atorvastatin and fenofibric acid on adipokine release from visceral and subcutaneous adipose tissue of patients with mixed dyslipidemia and normolipidemic subjects.

  Pharmacological reports : PR 20090101

• Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia.

  Journal of clinical lipidology 20081201

• Treatment of hyperlipidaemia with fenofibrate and related fibrates.

  Expert opinion on investigational drugs 20081001

• Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing.

  Vascular health and risk management 20081001

• Nanocrystal technology, drug delivery and clinical applications.

  International journal of nanomedicine 20080901

• PPARalpha regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes.

  Toxicology and applied pharmacology 20080815

• Characterization of the drug binding specificity of rat liver fatty acid binding protein.

  Journal of medicinal chemistry 20080710

• An automated method for the simultaneous determination of pravastatin, 3-hydroxy isomeric metabolite, pravalactone and fenofibric acid in human plasma by sensitive liquid chromatography combined with diode array and tandem mass spectrometry detection.

  Journal of chromatography. A 20080502

• A novel PPARalpha agonist ameliorates insulin resistance in dogs fed a high-fat diet.

  American journal of physiology. Endocrinology and metabolism 20080501

• Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers.

  European journal of pharmacology 20080428

• Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9.

  The Journal of biological chemistry 20080411

• Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.

  Bioorganic & medicinal chemistry letters 20080315

• Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.

  Bioorganic & medicinal chemistry 20080115

• Cryptochrome and Period Proteins Are Regulated by the CLOCK/BMAL1 Gene: Crosstalk between the PPARs/RXRalpha-Regulated and CLOCK/BMAL1-Regulated Systems.

  PPAR research 20080101

• Fenofibrate set to benefit from new research on its active metabolite, fenofibric acid.

  Cardiovascular journal of Africa 20080101

• Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.

  Clinical drug investigation 20080101

• Statins Activate Human PPARalpha Promoter and Increase PPARalpha mRNA Expression and Activation in HepG2 Cells.

  PPAR research 20080101

• Development and Validation of RP-HPLC Method for Simultaneous Estimation of Atorvastatin Calcium and Fenofibrate in Tablet Dosage Forms.

  Indian journal of pharmaceutical sciences 20080101

• Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid.

  Drug metabolism and disposition: the biological fate of chemicals 20070801

• Influence of HDL-cholesterol-elevating drugs on the in vitro activity of the HDL receptor SR-BI.

  Journal of lipid research 20070801

• Effects of peroxisome proliferator-activated receptor activation on gonadotropin transcription and cell mitosis induced by bone morphogenetic proteins in mouse gonadotrope LbetaT2 cells.

  The Journal of endocrinology 20070701

• Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein.

  The Journal of pharmacology and experimental therapeutics 20070501

• Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.

  Journal of medicinal chemistry 20070405

• Determination of fenofibric acid concentrations by HPLC after anion exchange solid-phase extraction from human serum.

  Therapeutic drug monitoring 20070401

• LC-MS analysis and environmental risk of lipid regulators.

  Analytical and bioanalytical chemistry 20070201

• Activating effect of benzbromarone, a uricosuric drug, on peroxisome proliferator-activated receptors.

  PPAR research 20070101

• Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.

  Bioorganic & medicinal chemistry letters 20061215

• Synthesis and evaluation of aminomethyl dihydrocinnamates as a new class of PPAR ligands.

  Bioorganic & medicinal chemistry letters 20061215

• Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha.

  The Journal of pharmacology and experimental therapeutics 20061201

• Aldehyde oxidase 1 is highly abundant in hepatic steatosis and is downregulated by adiponectin and fenofibric acid in hepatocytes in vitro.

  Biochemical and biophysical research communications 20061124

• The transfer of a LC-UV method for the determination of fenofibrate and fenofibric acid in Lidoses: use of total error as decision criterion.

  Journal of pharmaceutical and biomedical analysis 20060911

• Diphenylmethane skeleton as a multi-template for nuclear receptor ligands: preparation of FXR and PPAR ligands.

  Bioorganic & medicinal chemistry letters 20060615

• Effects of fenofibrate on C-reactive protein levels in hypertriglyceridemic patients.

  Journal of cardiovascular pharmacology 20060601

• Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review.

  International journal of nanomedicine 20060601

• The PPAR-alpha activator fenofibrate fails to provide myocardial protection in ischemia and reperfusion in pigs.

  American journal of physiology. Heart and circulatory physiology 20060501

• Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects.

  Clinical therapeutics 20060301

• Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation.

  International journal of clinical pharmacology and therapeutics 20060201

• The effects of food on the bioavailability of fenofibrate administered orally in healthy volunteers via sustained-release capsule.

  Clinical pharmacokinetics 20060101

• Optimal lipid modification: the rationale for combination therapy.

  Vascular health and risk management 20051201

• Simultaneous determination of rosuvastatin and fenofibric acid in human plasma by LC-MS/MS with electrospray ionization: assay development, validation and application to a clinical study.

  Journal of pharmaceutical and biomedical analysis 20050915

• Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders.

  Human molecular genetics 20050915

• Regulation of adiponectin receptor 1 in human hepatocytes by agonists of nuclear receptors.

  Biochemical and biophysical research communications 20050902

• Troglitazone and 15-deoxy-delta(12,14)-prostaglandin J2 inhibit shear-induced coupling factor 6 release in endothelial cells.

  Cardiovascular research 20050701

• Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport.

  Xenobiotica; the fate of foreign compounds in biological systems 20050701

• Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner.

  Arteriosclerosis, thrombosis, and vascular biology 20050601

• Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia.

  Journal of medicinal chemistry 20050407

• Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities.

  Journal of medicinal chemistry 20050324

• Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection.

  Gastroenterology 20050201

• Fenofibric acid.

  Acta crystallographica. Section C, Crystal structure communications 20050201

• 2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents.

  Bioorganic & medicinal chemistry letters 20050103

• Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes.

  Pharmaceutical research 20050101

• Gene expression profiling of potential peroxisome proliferator-activated receptor (PPAR) target genes in human hepatoblastoma cell lines inducibly expressing different PPAR isoforms.

  Nuclear receptor 20050101

• Fenofibrate, troglitazone, and 15-deoxy-Delta12,14-prostaglandin J2 close KATP channels and induce insulin secretion.

  The Journal of pharmacology and experimental therapeutics 20040901

• Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans.

  Journal of clinical pharmacology 20040901

• A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions.

  Clinical therapeutics 20040901

• Photosensitization of thymine nucleobase by benzophenone derivatives as models for photoinduced DNA damage: Paterno-Büchi vs energy and electron transfer processes.

  Chemical research in toxicology 20040701

• A novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose levels and modifies lipoprotein profiles in KK-Ay mice.

  The Journal of pharmacology and experimental therapeutics 20040601

• Fenofibrate and fenofibric acid analysis by capillary electrophoresis.

  Electrophoresis 20040601

• Cardiovascular drugs inhibit MMP-9 activity from human THP-1 macrophages.

  DNA and cell biology 20040501

• Influence of lipid lowering fibrates on P-glycoprotein activity in vitro.

  Biochemical pharmacology 20040115

• Effect of colesevelam HCl on single-dose fenofibrate pharmacokinetics.

  Clinical pharmacokinetics 20040101

• Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist.

  Journal of medicinal chemistry 20031120

• Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme.

  The Journal of biological chemistry 20030829

• Dilazep and fenofibric acid inhibit MCP-1 mRNA expression in glycoxidized LDL-stimulated human endothelial cells.

  European journal of pharmacology 20030815

• Identification of hepatic transcriptional changes in insulin-resistant rats treated with peroxisome proliferator activated receptor-alpha agonists.

  Journal of molecular endocrinology 20030601

• Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins.

  Molecular pharmacology 20030401

• An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers.

  Clinical therapeutics 20030201

• A chemical switch regulates fibrate specificity for peroxisome proliferator-activated receptor alpha (PPARalpha ) versus liver X receptor.

  The Journal of biological chemistry 20030124

• Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation.

  Clinical therapeutics 20021201

• Induction of plasminogen activator inhibitor-1 in endothelial cells by basic fibroblast growth factor and its modulation by fibric acid.

  Arteriosclerosis, thrombosis, and vascular biology 20020501

• A laser flash photolysis study of fenofibric acid in aqueous buffered media: unexpected triplet state inversion in a derivative of 4-alkoxybenzophenone.

  Photochemistry and photobiology 20020301

• PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells.

  European journal of pharmacology 20020125

• Randomised crossover studies of the bioequivalence of two fenofibrate formulations after administration of a single oral dose in healthy volunteers.

  Arzneimittel-Forschung 20020101

• Update on fenofibrate.

  Cardiovascular drug reviews 20020101

• Micronized fenofibrate in dyslipidemia: a focus on plasma high-density lipoprotein cholesterol (HDL-C) levels.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20020101

• Comparison of DNA damage photoinduced by ketoprofen, fenofibric acid and benzophenone via electron and energy transfer.

  Photochemistry and photobiology 20011101

• Regulation of lipid metabolism and gene expression by fenofibrate in hamsters.

  Biochimica et biophysica acta 20011031

• Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol.

  The Journal of rheumatology 20011001

• Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) alpha. PPAR alpha fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expresson.

  The Journal of biological chemistry 20010824

• PPARgamma ligands inhibit TNF-alpha-induced LOX-1 expression in cultured endothelial cells.

  Biochemical and biophysical research communications 20010824

• Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists.

  Journal of medicinal chemistry 20010621

• Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I.

  The Journal of clinical investigation 20010601

• Choice of lipid-regulating drugs.

  The Medical letter on drugs and therapeutics 20010528

• A potent PPARalpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle.

  American journal of physiology. Endocrinology and metabolism 20010201

• PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages.

  Circulation 20010116

• Rapid and simple method for detection of fenofibric acid in human serum by high-performance liquid chromatography.

  Die Pharmazie 20010101

• Drug treatment of combined hyperlipidemia.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20010101

• A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity.

  Journal of medicinal chemistry 19990923